Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metronidazole-induced cerebellar toxicity.
Chatzkel JA, Vossough A. Chatzkel JA, et al. Pediatr Radiol. 2010 Aug;40(8):1453. doi: 10.1007/s00247-009-1453-9. Epub 2009 Nov 14. Pediatr Radiol. 2010. PMID: 19915830 No abstract available.
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma.
Chatzkel J, Lewis JS Jr, Ley JC, Wildes TM, Thorstad W, Gay H, Daly M, Jackson R, Rich J, Paniello R, Nussenbaum B, Liu J, Siegel BA, Dehdashti F, Adkins D. Chatzkel J, et al. Head Neck Pathol. 2017 Sep;11(3):338-345. doi: 10.1007/s12105-016-0775-9. Epub 2016 Dec 26. Head Neck Pathol. 2017. PMID: 28025779 Free PMC article.
Tivozanib for the treatment of advanced renal cell carcinoma.
Chatzkel J, Ramnaraign B, Sonpavde G. Chatzkel J, et al. Expert Opin Pharmacother. 2022 Jul;23(10):1135-1142. doi: 10.1080/14656566.2022.2102419. Epub 2022 Jul 25. Expert Opin Pharmacother. 2022. PMID: 35848061
Immunotherapy Management in Special Cancer Patient Populations.
Ramnaraign BH, Chatzkel JA, Al-Mansour ZA, Rogers S, Jones D, DeRemer D, George TJ. Ramnaraign BH, et al. Among authors: chatzkel ja. JCO Oncol Pract. 2021 May;17(5):240-245. doi: 10.1200/OP.20.00996. Epub 2021 Mar 12. JCO Oncol Pract. 2021. PMID: 33710933 Review.
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. George TJ, et al. Among authors: chatzkel ja. JCO Precis Oncol. 2024 Dec;8:e2400406. doi: 10.1200/PO-24-00406. Epub 2024 Dec 3. JCO Precis Oncol. 2024. PMID: 39626160 Free PMC article. Clinical Trial.
14 results